Knight Announces Relaunch of AKYNZEO® in Canada
MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO (netupitant/palonosetron capsules) in Canada.
- MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO (netupitant/palonosetron capsules) in Canada.
- Knight and Helsinn Healthcare SA ("Helsinn") entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV (palonosetron) in Canada (the "Products") in May 2022.
- According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021.
- Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.